Efficacy of tacrolimus plus narrowband ultraviolet B phototherapy versus narrowband ultraviolet B phototherapy alone in the treatment of vitiligo

Authors

  • Ghafoor Ullah Nowshera Medical College, Nowshera
  • Somaiya Rehman Lady Reading Hospital Peshawar
  • Sahibzada Mehmood Noor
  • Muhammad Majid Paracha

DOI:

https://doi.org/10.66344/jpad.27.3.2017.927

Keywords:

Efficacy, Tacrolimus, Narrow Band, Vitiligo.

Abstract

Objective To compare the efficacy of tacrolimus plus narrowband ultraviolet B (NB-UVB) phototherapy versus  NB-UVB phototherapy alone in the treatment of vitiligo . Methods A total of 94 patients were randomized into two equal groups A and B. Patients in group A were managed with combined treatment i.e. NB-UVB three times a week plus topical tacrolimus 0.1% once daily application while patients in group B will be subjected to NB-UVB alone three times a week alone for three months. The efficacy was determined in term of repigmentation by measuring vitiligo area severity score. Results 41 (87.2%) patients in group A achieved efficacy while group B showed efficacy in 32 (68.1%) patients (p=0.022). Efficacy was unrelated to age, sex, severity and duration of vitiligo. Conclusion Combination therapy is more effective than monotherapy in the treatment of vitiligo. 

Author Biography

Ghafoor Ullah, Nowshera Medical College, Nowshera

Senior RegistrarDermatology

Downloads

Published

2018-03-15

How to Cite

1.
Ullah G, Rehman S, Noor SM, Paracha MM. Efficacy of tacrolimus plus narrowband ultraviolet B phototherapy versus narrowband ultraviolet B phototherapy alone in the treatment of vitiligo. J Pak Assoc Dermatol [Internet]. 2018Mar.15 [cited 2026Apr.21];27(3):232-7. Available from: https://www.jpad.com.pk/index.php/jpad/article/view/927

Issue

Vol. 27 No. 3 (2017): July - September

Section

Original Articles

License

Submission declaration

Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.

By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.